A Mazumder

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

EA Grimm, KM Ramsey, A Mazumder et al. · The Journal of Experimental Medicine · 1983 · 469 citations · Full text

Life Sciences, Immunology, Oncology +14

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

Paul G. Richardson, Sundar Jagannath, David Avigan et al. · Blood · 2006 · 68 citations

Medicine, Hematology, Pharmacotherapy +17

Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.

R Agah, Beth Malloy, M Kerner et al. · The Journal of Immunology · 1989 · 46 citations

Life Sciences, Immunology, Oncology +16

The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease.

Andrew L. Gilman, F Beams, Mariella C. Tefft et al. · PubMed · 1996 · 37 citations

Life Sciences, Immunology, Immunopathology +10